Affimed Shares Outstanding 2014-2021 | AFMD

Affimed shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Affimed Annual Shares Outstanding
(Millions of Shares)
2020 83
2019 64
2018 61
2017 44
2016 33
2015 28
2014 26
2013 16
2012 16
Affimed Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 120
2021-03-31 116
2020-12-31 83
2020-09-30 86
2020-06-30 79
2020-03-31 76
2019-12-31 64
2019-09-30 62
2019-06-30 62
2019-03-31 62
2018-12-31 61
2018-09-30 64
2018-06-30 62
2018-03-31 55
2017-12-31 44
2017-09-30 45
2017-06-30 44
2017-03-31 41
2016-12-31 33
2016-09-30 33
2016-06-30 34
2016-03-31 34
2015-12-31 33
2015-09-30 30
2015-06-30 27
2015-03-31 25
2014-12-31 24
2014-09-30 3
2014-06-30 15
2014-03-31 15
2013-09-30 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.611B $0.032B
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29